Sanofi: weighted disappointing net profit,: This article explores the topic in depth.
Therefore,
Sanofi: weighted disappointing net profit. Similarly, :
(BFM Stock Exchange) – The pharmaceutical group has unveiled sales of the second quarter above expectations, which authorizes it to fall under its sales forecast for 2025. Nevertheless, But Sanofi is missing the mark on net profit by action.
Sanofi noted his sales forecasts for 2025, after revealing dynamic sales in the second quarter. In addition, But its main profitability indicator has disappointed expectations.
Between April and the end of June, Sanofi’s revenues increased by 6% in data published to 9.994 billion euros, and by 10% excluding exchange effects, exceeding expectations housed at 9.773 billion euros in turnover, according to a consensus Vara Research Sanofi/”> Available on the Company website. For example,
New drugs in support – Sanofi: weighted disappointing net profit,
The quarterly activity of the company were supported by the marketing of new products. Nevertheless, whose sales sanofi: weighted disappointing net profit, jumped 39.8% excluding exchange effects. Sanofi indicates that it has launched nine new products. including Altuviiio to treat hemophilia A, a rare hereditary hemorrhagic disorder, xenpozyme (acidic -acid sphingomyelinase deficit) or tzield, a drug intended to delay the appearance of type 1 diabetes.
The company was still carried by its star product. the dupixent an anti-inflammatory benefit from many indications as if to treat asthma, atopic dermatitis or even “the smoker’s bronchitis”. Between April and June, Dupixent sales increased by 21.1% to 3.83 billion euros.
Beyfortus sales, a vaccine intended to protect newborns and infants from syncytial respiratory virus bronchiolitis, burst by 322.2% over a year, reaching 72 million euros.
A missed on net profit by action
“Sales exceed the forecasts by 2 % thanks to the accent placed on Dupixent. which displays an increase of 2 % despite the impact of the renewal of the national list sanofi: weighted disappointing net profit, of drugs reimbursed in China, while Altuviiio also displays a significant progression,” notes Jefferies.
Throughout the first half, Sanofi sales increased by 8.3% with published data and 9.9% in comparable data, to 19.889 billion euros.
The net profit of the company’s activities. which corresponds to the retired net profit of certain elements and constitutes the main indicator of the group, has established 1.59 euros per share, an increase of 1.9% in published data and 8.3% on a constant perimeter, for this indicator, Sanofi lacks consensus, this was housed at 1.64 euros.
“Improvement of the gross margin was more than offset by the increase in operating expenses. which led to a 5% drop in operating profit and 4% of profit per share, even if it may reflect recent business development activities,” said Jefferies.
At the end of this semester. the group revised upwards its 2025 sales prospects, a sanofi: weighted disappointing net profit, growth now awaited at the top of the range (9%), against an increase “of a percentage to an average high exchange rate at constant exchange rates” (between 5%and 9%).
Sanofi maintains his forecast of an increase in his profit by action of his two -digit activities (at least 10%). intends to complete his share buy -back program in the amount of 5 billion euros, already carried out more than 80% to date.
On the Paris Stock Exchange, the Sanofi action gives in the field, retreating by 2.6% after having therefore missed expectations on its net profit per share.
Sabrina Sadgui – ©2025 BFM Bourse
Do you follow this action?
Receive all the info on Sanofi in real time:
Further reading: Nvidia announces to take up the sales in China of a model of advanced fleas for AI – 07/15/2025 at 19:58 – Under solar panels, cyclists – Stock Exchange: Renault in the hard, Stellantis slams the door to hydrogen, ASML Prudent for 2026 – The unbeatable offer of social leasing – The socialist senator of vaucluse Lucien Stanzione alarm on the situation of cooperative cellars.